Angiography with a co-registered view of pressure drops according iFR readings in a coronary vessel. The DEFINE PCI study showed patients had improved outcomes and less recurrent chest pain at one year using iFR physiologic measurements combined with landmarks shown on angiographic imaging to better guide therapy. Image by Philips Healthcare. #TCT #TCT2020 #TCTconnect
Feature | FFR Technologies | Dave Fornell, Editor
FFR Studies Find Several Surprises at TCT 2020

Fractional flow reserve (FFR) is considered the gold standard measure whether a coronary lesions needs a percutaneous ...

Home October 30, 2020
Home
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020
Feature | TCT | Dave Fornell, Editor
Top 10 Takeaways on Interventional Technologies at TCT 2020

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe.
Feature | Magnetic Resonance Imaging (MRI)
Cardiac MRI Contrast Agents Carry Low Risk of Adverse Events

October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a very ...

Home October 29, 2020
Home
The Watchman FLX will be tested in the CHAMPION-AF trial looks at next-generation transcatheter LAA device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation.
News | Atrial Fibrillation
Boston Scientific Initiates Trial to Evaluate Watchman FLX LAA Closure Device as First-Line Treatment

Oct. 29, 2020 — Boston Scientific initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the ...

Home October 29, 2020
Home
A sonographer at Northwestern Memorial Hospital using the Caption Health AI to optimize ultrasound imaging. Northwestern Memorial Hospital in Chicago is the first in U.S. to adopt Caption AI (artificial intelligence) to improve ultrasound imaging in emergency department, ICU and cardio-oncology clinic  
News | Ultrasound Imaging
Northwestern Medicine Introduces Artificial Intelligence to Improve Ultrasound Imaging

October 28, 2020 — Northwestern Memorial Hospital is the first hospital in the United States to purchase Caption Health ...

Home October 28, 2020
Home
The September-October 2020 digital edition of Diagnostic and Interventional Cardiology (DAIC) magazine. Dave Fornell is the editor. #DAIC
News
View the DAIC Sept-Oct 2020 Digital Edition

The September-October 2020 digital edition of Diagnostic and Interventional Cardiology (DAIC) magazine include links to ...

Home October 28, 2020
Home
Chest X-ray, posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.
Feature | Magnetic Resonance Imaging (MRI)
MRI Can Be Safely Performed in Patients With Pacemakers and ICDs

October 27, 2020 – Magnetic resonance imaging (MRI) examinations can be safely performed in patients with non-MR ...

Home October 27, 2020
Home
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 
Feature | ECMO Systems
FDA Clears Abiomed Compact ECMO System for COVID-19 and Cardiogenic Shock Patients

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-one ...

Home October 26, 2020
Home
Abre venous self-expanding stent found safe, effective in treating challenging deep venous lesions was approved by the FDA.
News | Venous Therapies
Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

Home October 26, 2020
Home
Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system. #TCT2020 #TCTconnect
News | Pulmonary Embolism
Acute Hemodynamic Improvement With Percutaneous Mechanical Thrombectomy in a Real-world Pulmonary Embolism Population

October 23, 2020 — Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world ...

Home October 23, 2020
Home
Fractional Flow reserve (FFR) selection on the Abbott, St. Jude FFR system console. The TARGET FFR study at #TCT2020 #TCTconnect.
News | FFR Technologies
FFR-guided PCI Optimization Strategy May Lead to Improved Outcomes

October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided ...

Home October 23, 2020
Home
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone actually was not flow limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings. #TCT2020 #TCTconnect
News | FFR Technologies | Dave Fornell, Editor
FFR-CT Did Not Significantly Reduce Costs But Reduced Rates of Invasive Coronary Angiography

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from ...

Home October 22, 2020
Home
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect
Feature | Stents | Dave Fornell, Editor
Durable Polymer Drug-Eluting Stents Perform Better Than Biodegradable Polymer DES

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

Home October 22, 2020
Home
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents
Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

Home October 22, 2020
Home
Videos | Hemodynamic Support Devices
VIDEO: Abiomed Highlights Trends and New Technology in Hemodynamic Support

Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...

Home October 20, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now